Characterization of Elvitegravir and Its Related Impurities Using ESI–LC–MS, NMR Techniques, Method Development and Validation of Its Related Substances by HPLC Method-Reference-Cited by-同舟云学术

Characterization of Elvitegravir and Its Related Impurities Using ESI–LC–MS, NMR Techniques, Method Development and Validation of Its Related Substances by HPLC Method

Published:2024-02-22 Issue:4 Volume:87 Page:227-248
ISSN:0009-5893
Container-title:Chromatographia
language:en
Short-container-title:Chromatographia

Author:

Elumalai Sambandan,Senthilkumar Sellappan,Srikanth Mamidala,Nishtala Venkata Bharat,Thenmozhi Kathavarayan

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10337-024-04314-2.pdf

Reference40 articles.

1. Prada N, Markowitz M (2010) Novel integrase inhibitors for HIV. Expert Opin Investig Drugs 19:1087–1098. https://doi.org/10.1517/13543784.2010.501078

2. Siberry GK, Hazra R (2018) 113-Management of HIV infection. In: Long SS, Fischer M, Prober CG (eds) principles and practice of pediatric infectious diseases, 5 edn. Elsevier, Amsterdam, p 681.e2. https://doi.org/10.1016/B978-0-323-40181-4.00113-4

3. Eckhardt BJ, Gulick RM (2017) 152—drugs for HIV infection. In Cohen J, Powderly WG, Opal SM (eds) Infectious diseases, 4 edn. Elsevier, Amsterdam, pp 1293–1308. e2. https://doi.org/10.1016/B978-0-7020-6285-8.00152-0

4. Tsibris AMN, Hirsch MS (2015) 130—antiretroviral therapy for human immuno deficiency virus infection. In: Bennett JE, Dolin R, Blaser MJ, Mandell, Douglas (eds) Principles and practice of infectious diseases, 8 edn. WB Saunders, Elsevier, Amsterdam, pp 1622–1641. e6. https://doi.org/10.1016/B978-1-4557-4801-3.00130-2

5. Waller DG, Sampson AP (2018) 51—chemotherapy of infections. In: Waller DG, Sampson AP (eds) Medical pharmacology and therapeutics, 5 edn. Elsevier, Amsterdam, p 581. https://doi.org/10.1016/B978-0-7020-7167-6.00051-8